Vivos Therapeutics, Inc. (VVOS): Business Model Canvas [Dec-2025 Updated]

You're looking at a company in a major strategic shift, and as an analyst, that's where the real money-or the real risk-is found. Vivos Therapeutics, Inc. is fundamentally moving away from relying on dentist training fees to a direct, vertically integrated patient care model by acquiring medical sleep centers like The Sleep Center of Nevada. Honestly, this aggressive pivot is driving revenue, but it's also widening the net loss to $14.3 million year-to-date through Q3 2025; that's the price of vertical integration right now. I've defintely seen this play before. Dive into the nine blocks of their new Business Model Canvas below to see exactly how they plan to turn that cash burn into sustainable value for OSA patients and investors.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Key Partnerships

You're looking at Vivos Therapeutics, Inc.'s (VVOS) shift from a dentist-centric training model to one focused on direct patient care through medical center alliances, so the partnerships section of the Business Model Canvas reflects this pivot heavily as of late 2025.

Strategic alliances with sleep-focused medical practices

The core of the new model is the acquisition and integration of high-volume sleep centers, exemplified by The Sleep Center of Nevada (SCN). This alliance structure allows Vivos Therapeutics to capture both diagnostic and treatment revenue directly.

• SCN, acquired in June 2025, is the largest operator of medical sleep centers in Nevada.
• SCN historically served over 200,000 obstructive sleep apnea (OSA) patients since 2019.
• As of the June 2025 acquisition, SCN had seven locations and nearly 50 beds for overnight PSG testing.
• Management projected deploying 3.5 Sleep Optimization (SO) teams at SCN by year-end 2025.
• Each fully operational SO team is projected to process up to 250 patients monthly.
• Approximately 90% of SCN patients test positive for OSA or other sleep disorders.

Legacy network of Vivos Integrated Providers (VIPs)

The legacy model relied on training dentists, a revenue stream Vivos Therapeutics is actively weaning off of to focus on the new model. Still, the historical scale is important context for the existing installed base.

Here's the quick math on the legacy network as of year-end 2024:

Metric	Value
Dentists Trained in The Vivos Method	More than 2,000
Patients Treated Worldwide (Legacy)	Approximately 58,000
VIP Service Revenue (Q1 2025 vs Q1 2024)	Decreased, contributing to a revenue decline from $3.4 million to $3.0 million

Debt and equity financing partners like Seneca Partners

Financing these strategic moves, especially the SCN acquisition, required significant capital from key financial partners. The cost of this capital is something management is actively looking to reduce.

• Vivos Therapeutics raised $11.5 million net through debt and equity to fund the SCN acquisition and expansion as of Q2 2025.
• Seneca Partners (via New Seneca Partners Inc.) was a major investor in this recent capital raise.
• An earlier equity investment from New Seneca Partners Inc. in 2024 totaled $7.5 million.
• Vivos also entered a $1,100,000 convertible promissory note with an affiliate of New Seneca Partners Inc. in May 2025.
• The over $11 million financing for the SCN acquisition also included a senior secured loan from Streeterville Capital.
• As of June 30, 2025, the company reported $4.4 million in cash and $21.5 million in total liabilities.

Dental laboratories for manufacturing oral appliances

This segment involves the operational backbone for delivering the core product, the oral appliance. While the pivot emphasizes service revenue capture, the physical product supply chain remains critical.

The search results confirm the existence of this relationship for manufacturing, but do not provide specific 2025 statistical or financial metrics regarding the number of labs or their transaction volumes.

Functional medicine doctors and sleep specialists

The new model explicitly targets sleep-focused medical practices, moving beyond the legacy dentist-only focus. The SCN acquisition itself is the prime example of this partnership with medical doctors (MDs) and sleep specialists.

• The SCN team includes lead sleep MDs who endorsed the Vivos treatment as a viable alternative to CPAP.
• Vivos is exploring similar arrangements in other states following the SCN integration, which is expected to see remodeled facilities open around October 2025.
• The company aims to expand into Michigan under a new management collaboration.

Finance: review the Q3 2025 debt covenant compliance by end of next week.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Key Activities

Integrating acquired sleep centers, like SCN, into the Vivos Method

Vivos Therapeutics, Inc. completed the acquisition of The Sleep Center of Nevada (SCN) on June 10, 2025. SCN is the largest operator of medical sleep centers in Nevada, bringing seven locations and nearly 50 beds for overnight PSG testing under Vivos\' management. SCN historically served approximately 3,000 new patients monthly and has diagnosed and treated over 200,000 sleep disorder cases. The acquisition was valued at $9 million in cash and stock with potential earn-outs. Integration has begun at two SCN locations, with full ramp-up anticipated over the next 12-18 months. Vivos is exploring similar arrangements in other states, with expansion into Michigan on deck by December 2025.

SCN Metric	Data Point
Acquisition Date	June 10, 2025
SCN Locations	7
SCN Beds for PSG Testing	Nearly 50
SCN New Patients Monthly (Historical)	Approximately 3,000
SCN Positive OSA Diagnosis Rate	90 percent
SCN Diagnostic Revenue (Q2 2025, 20 days)	Approximately $500,000
SCN Diagnostic Revenue (Q3 2025)	$2.2 million
SCN Treatment Center Revenue (Q3 2025)	$1.3 million
Acquisition Financing (Senior Loan Principal)	$8,225,000

Manufacturing and distributing proprietary oral appliances

Vivos Therapeutics, Inc. sold 3,736 oral appliance arches in the first quarter of 2025, generating approximately $1.8 million in revenue from product sales. This represented an 8% year-over-year increase in product revenue for Q1 2025 compared to Q1 2024. The gross margin for the second quarter of 2025 was 55%, declining to 58% in the third quarter of 2025. For the nine months ended September 30, 2025, the gross margin was 55%.

Period Ended March 31, 2025 (Q1)	Value
Oral Appliance Arches Sold	3,736
Product Revenue	Approximately $1.8 million
Product Revenue YoY Growth	8%

Deploying Sleep Optimization (SO) teams to scale operations

The deployment of Vivos sleep optimization teams is expected to further ramp up revenue streams generated by the SCN acquisition, specifically the $1.3 million in treatment center revenue recognized in Q3 2025.

Conducting clinical education and training for providers

Vivos Therapeutics, Inc. is actively pivoting away from its legacy Vivos Integrated Provider (VIP) model, which previously relied on subscription and enrollment fees. The recognition of legacy VIP enrollment revenue is expected to be finished by the end of 2026. In the prior year (Q4 2023), signed Dentist Enrollment Contracts increased 38% sequentially over Q3 2023.

• Legacy VIP enrollment revenue recognition expected to cease by end of 2026.

Securing regulatory clearances (e.g., FDA) for devices

Vivos Therapeutics, Inc. devices have FDA 510(k) clearance for adult patients with all severity levels of OSA. The company also has clearance for moderate-to-severe OSA in children ages 6 to 17. The CARE oral medical devices are the only FDA 510(k) cleared technology for treating severe OSA in adults and the first cleared for treating moderate to severe OSA in children. New Current Procedural Terminology (CPT) coverage and reimbursement codes applicable to all Vivos CARE oral medical devices became effective Jan. 1, 2025.

• FDA Clearance for severe OSA in adults: Nov. 2023.
• FDA Clearance for moderate-to-severe OSA in children: Sept. 2024.
• New CPT Codes Effective: January 1, 2025.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Key Resources

Proprietary, FDA-cleared Vivos System/Method technology

• Vivos Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe Obstructive Sleep Apnea (OSA) in adults and the first to receive clearance for treating moderate to severe OSA in children ages 6 to 17.
• FDA 510(k) clearance for severe OSA in adults received in November 2023.
• The Vivos Method has proven effective in approximately 45,000 patients treated worldwide by more than 2,000 trained dentists as of September 2024.

Acquired medical sleep center infrastructure (e.g., SCN)

Vivos Therapeutics completed the acquisition of The Sleep Center of Nevada (SCN) in June 2025. SCN historically served over 200,000 sleep disorder cases since 2019.

Metric	Value
SCN Acquisition Total Value	Up to $9 million
SCN Upfront Cash Payment	$6 million
SCN Q3 2025 Diagnostic Sleep Testing Revenue	$2.2 million
SCN Q3 2025 Treatment Center Revenue	$1.3 million

Intellectual property (patents) protecting the oral appliance design

• Acquired certain U.S. and international patents, provisional patent applications, PCT patents, and patent applications from Advanced Facialdontics, LLC in March 2023.
• U.S. Design Patent USD731659S1, assigned to Vivos Therapeutics, Inc. on 2018-03-20, has an anticipated expiration of 2029-06-09.

Cash and cash equivalents of $3.1 million as of Q3 2025

Financial Metric (as of September 30, 2025)	Amount
Cash and Cash Equivalents	$3.1 million
Stockholders' Equity	$2.5 million
Total Liabilities	$23.1 million
Q3 2025 Revenue	$6.8 million
Nine Months Ended September 30, 2025 Operating Loss	$13.5 million

Specialized Sleep Optimization (SO) personnel and clinical staff

• Management planned to have 3.5 SO teams operating at SCN by year-end 2025.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Value Propositions

Non-surgical, non-invasive treatment for Obstructive Sleep Apnea (OSA)

Vivos Therapeutics, Inc. offers proprietary oral appliances as a non-surgical alternative for treating sleep related breathing disorders. The company's devices are FDA 510(k) cleared for adult patients diagnosed with all severity levels of OSA.

Clinically effective solution for all severities of adult OSA

The core value is providing an effective treatment pathway that avoids traditional invasive procedures for adults with OSA. The company's groundbreaking Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k) cleared technology for treating severe OSA in adults.

Treatment for moderate-to-severe OSA in children (ages 6-17)

Vivos Therapeutics, Inc. holds the first oral device clearance for treating moderate to severe OSA in children aged 6 to 17. This addresses a significant unmet need, as an estimated 10 million U.S. children have pediatric OSA, with up to 90% remaining undiagnosed.

The clinical effectiveness data for the DNA appliance in pediatric patients is compelling:

Metric	Result
Reduction in OSA Severity (at least 50%)	77% of participants
Reduction in OSA Severity (Severe OSA patients)	93% reached at least 50% reduction
Complete Resolution of OSA	17% of participants
Average Airway Volume Increase	67.8%
Average PSQ Symptom Score Decrease	31%

Further data suggests broader benefits from Vivos treatment protocols:

• 61% of children with OSA reported their ADHD symptoms completely resolved or rarely occurred after seven months of treatment.
• 90% of children had their OSA symptoms completely resolved after a similar treatment period in a separate study.
• For bedwetting, 50% saw results within two weeks, and 97.4% resolved within 60 days using Vivos Guides.

Direct access to diagnostic and treatment services via sleep centers

The company is pivoting its model to focus on direct relationships with patients through sleep-focused medical practices. This strategy was highlighted by the acquisition of The Sleep Center of Nevada (SCN) on June 10, 2025. SCN alone sees thousands of OSA patients per month who are candidates for treatment. The impact of this pivot is visible in the Q3 2025 results, which showed a $2.2 million increase in OSA sleep testing services revenue, primarily generated by SCN. The average case value for Vivos appliances at SCN is currently just over $5,000.

Potential to address the root cause of dentofacial abnormalities

Vivos Therapeutics, Inc. specializes in developing methods for patients whose breathing and sleep issues arise from certain dentofacial abnormalities. The FDA clearance for pediatric use specifically covers children ages 6 to 17 who also have malocclusions that may require orthodontics.

The global scale of the problem is immense: OSA affects over 1 billion people worldwide, yet 90% remain undiagnosed.

Finance: review SCN integration cost projections against the Q3 2025 OpEx of $8.7 million by next Tuesday.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Customer Relationships

You're looking at how Vivos Therapeutics, Inc. (VVOS) manages its patient and provider relationships now that they've pivoted hard toward owning the patient journey. The focus has clearly shifted from a pure B2B model with dentists to a high-touch, direct-to-patient service via owned medical centers. This is where the real action is for their 2025 strategy.

Direct, high-touch clinical service through owned/affiliated sleep centers is the new core. The June 2025 acquisition of The Sleep Center of Nevada (SCN), the largest operator of medical sleep centers in Nevada, is the prime example of this. SCN historically served over 200,000 Obstructive Sleep Apnea (OSA) patients since 2019. Now, Vivos Therapeutics, Inc. (VVOS) has direct access to that patient flow. SCN sees approximately 3,000 new patients monthly for testing and consultation, with about 90% testing positive for OSA or related conditions. The company is actively pursuing more affiliations and acquisitions of sleep medicine practices nationwide. Even in the initial alliance with Rebis Health in Colorado, data showed a Vivos treatment case acceptance rate of 64%, which is nearly 2:1 over CPAP.

The operational structure supporting this direct service is built around the Dedicated Sleep Optimization (SO) teams for patient care. Management projected deploying 3.5 SO teams specifically in Las Vegas by year-end 2025. Each team is structured to be comprehensive, comprising about 16 cross-functional staff members. The financial expectation for these teams is significant; each fully operational SO team is projected to process up to 250 patients monthly, potentially generating over $500,000 in monthly net collections with contribution margins targeted above 50%. The impact of this new model is visible in the Q3 2025 results, where SCN contributed $2.2 million in OSA sleep testing services revenue and $1.3 million from treatment centers in that quarter alone.

The transition means Vivos Therapeutics, Inc. (VVOS) is deliberately moving away from its older relationships, specifically the Professional training and support for legacy VIP dentists. This legacy VIP fee revenue is being phased out, with management expecting to finish recognizing it by the end of 2026. For context, in the first nine months of 2025, VIP revenue decreased by approximately $2.6 million compared to the same period in 2024. This shift is a conscious effort to capture immediate diagnostic and treatment revenue rather than relying on the dentist training channel, which, as of the end of 2024, had trained over 2,000 dentists.

The focus on SO teams and owned centers inherently drives Patient-centric follow-up and long-term care management, as these teams are responsible for the full patient journey through the Vivos CARE treatment. The success in building trust with medical sleep specialists for referrals is demonstrated by the SCN acquisition, where the existing medical team showed strong buy-in, with two lead sleep MDs becoming very early patients themselves. This is a stark contrast to the pre-acquisition SCN, which historically referred 95% of its OSA patients to CPAP or surgery.

Here's a quick look at the key relationship metrics following the model pivot:

Metric Category	Key Metric/Data Point	Value (as of late 2025)	Source Context
Direct Access - Patient Volume	SCN New Patients Per Month	3,000	The Sleep Center of Nevada (SCN) monthly intake
Direct Access - Case Acceptance	Vivos Treatment Acceptance Rate (Alliance Data)	64% (nearly 2:1 over CPAP)	Initial data from Rebis Health Alliance
SO Team Capacity	Projected SO Teams in Las Vegas (Year-End 2025)	3.5 teams	Management projection for SCN integration
SO Team Throughput	Projected Patients Processed Per Team Monthly	Up to 250 patients	Projection for fully operational SO teams
Legacy Relationship Decline	Decrease in VIP Revenue (9M 2025 vs 9M 2024)	$2.6 million decrease	Impact of weaning off legacy business
SCN Revenue Contribution	OSA Sleep Testing Revenue in Q3 2025	$2.2 million	SCN's contribution in its first full quarter

The company is defintely prioritizing these direct, high-touch relationships, which is why operating expenses rose to $7.0 million in Q2 2025 due to the investment in personnel and infrastructure for this new model. Finance: draft the Q4 2025 SO team utilization report by January 15, 2026.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Channels

You're looking at the channels Vivos Therapeutics, Inc. (VVOS) uses to get its Complete Airway Repositioning and Expansion (CARE) devices and services to patients as of late 2025. The company has clearly pivoted its primary channel strategy, moving from a heavy reliance on dental providers to direct patient care via acquired medical practices.

Owned/Acquired Medical Sleep Centers (e.g., SCN in Nevada)

The acquisition of The Sleep Center of Nevada (SCN) in June 2025 is the cornerstone of the new channel approach. This move shifts Vivos Therapeutics, Inc. to directly operating high-volume sleep testing and treatment centers.

• The SCN acquisition, finalized in June 2025, involved a deal valued at up to $9 million in cash and stock plus potential earn-outs.
• SCN operates a seven-location network in Nevada.
• SCN historically serves around 3,000 new patients monthly.
• For the nine months ended September 30, 2025, SCN generated approximately $2.8 million in sleep testing services revenue.
• SCN contributed $2.2 million in increased OSA sleep testing services revenue in the third quarter of 2025 alone.
• Vivos Therapeutics, Inc. projected having 3.5 Sleep Optimization (SO) teams operating at SCN by the end of 2025.
• Each fully operational SO team is projected to process up to 250 patients per month, targeting over $500,000 in monthly net collections.
• The company is exploring similar arrangements in other states and expects to expand into Michigan under a new management collaboration.

This direct channel is already showing impact; Vivos Therapeutics, Inc. recognized approximately $500,000 of diagnostic sleep testing services revenue from SCN over just 20 days following the June 10, 2025 closing date in Q2 2025. That's a fast start for a new channel.

Direct Sales Force Targeting Medical Sleep Providers

While the focus is direct patient care through owned centers, the sales structure is adapting to support this new model and potentially new provider alliances.

Metric	Value/Status (as of late 2025 data)
New Treatment Center Revenue (9M ended 9/30/2025)	$1.6 million increase, attributable to new treatment centers.
SO Team Expansion Goal (Year-End 2025)	3.5 teams projected at SCN.
Projected Monthly Net Collections per SO Team	Over $500,000.

The company is actively working to expand its physical facilities and recruit/hire/train additional providers and staff to handle patient demand generated through these direct channels. It's a clear shift from the previous structure.

Network of Trained Vivos Integrated Provider (VIP) Dentists

This represents the legacy channel, which Vivos Therapeutics, Inc. is actively pivoting away from in favor of the higher-margin, direct-to-patient model.

• The company is continuing its pivot away from legacy Vivos Integrated Provider (VIP) fee revenue.
• For the first quarter of 2025, revenue declined year-over-year, which was expected due to lower service revenue resulting from this pivot away from VIP service revenue.
• As of December 31, 2024, Vivos had trained more than 2,000 dentists in The Vivos Method.
• The Vivos Method had proven effective in approximately 58,000 patients treated worldwide by these trained dentists as of year-end 2024.

The focus now is on driving appliance sales through provider-based acquisitions and alliances, rather than just training fees from the VIP program.

Telemedicine and Home Sleep Testing Services

The VivoScore program, which utilizes SleepImage diagnostic technology, remains a component of the overall offering, often integrated within the new center model.

• SCN contributed approximately $200,000 in additional product revenue in Q3 2025.
• Vivos sold 3,736 oral appliance arches in Q1 2025, totaling approximately $1.8 million in revenue from product sales.

Investor Relations and Public Market Communications

Communication channels are focused on transparency regarding the strategic shift and capital needs to fund the new direct-care model.

Communication/Financial Event	Date/Amount
Q3 2025 Financial Results Release	November 19, 2025
Net Cash from Financing Activities (Q3 2025)	$14.2 million
Cash and Cash Equivalents (as of 9/30/2025)	$3.1 million
Total Liabilities (as of 9/30/2025)	$23.1 million
Stockholders' Equity (as of 9/30/2025)	$2.5 million

The company raised capital in 2025, including an equity financing from an affiliate of Cynica Partners, to support the SCN acquisition and expansion efforts.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Customer Segments

You're hiring before product-market fit, so knowing exactly who you are selling to-and what problem you solve for them-is the first step to getting the numbers right. Vivos Therapeutics, Inc. (VVOS) targets a broad spectrum of individuals suffering from sleep-related breathing disorders, primarily Obstructive Sleep Apnea (OSA), while also engaging the medical professionals who diagnose and treat them.

Adults diagnosed with all severities of Obstructive Sleep Apnea (OSA)

The overall market for OSA is massive, but Vivos Therapeutics, Inc. (VVOS) is focused on those seeking a non-lifetime intervention. OSA affects over 1 billion people worldwide, yet 90% of those individuals remain undiagnosed and unaware of their condition. Vivos Therapeutics, Inc. (VVOS) has treated more than 60,000 patients worldwide with its Complete Airway Repositioning and Expansion (C.A.R.E.) devices, which are FDA 510(k) cleared for treating severe OSA in adults.

Children (ages 6-17) with moderate-to-severe OSA

This segment represents a significant, often undertreated, population where Vivos Therapeutics, Inc. (VVOS) has achieved key regulatory milestones. Up to 20.4% of U.S. children, equating to as many as 10 million, are estimated to be living with pediatric OSA, with up to 90% of these children remaining undiagnosed. Vivos Therapeutics, Inc. (VVOS) received FDA 510(k) clearance for its DNA appliance to treat moderate to severe OSA in children aged 6 to 17. Clinical trial data from 2025 showed compelling results for this group:

• 77% of participants experienced at least a 50% reduction in OSA severity.
• Among children with severe OSA, 93% reached a 50% reduction in their symptoms.
• 17% of patients in the study achieved complete resolution of their OSA.
• Airway volume increased by an average of 67.8%.
• In one study, 97.4% of children saw bedwetting resolve within 60 days.
• 61% of children with OSA reported their ADHD symptoms were completely resolved or rarely occurred after just seven months of treatment.

Medical sleep specialists and pulmonologists

This group is a critical channel for diagnosis and treatment referral, especially following Vivos Therapeutics, Inc. (VVOS)'s strategic pivot toward medical sleep centers. The company completed the acquisition of The Sleep Center of Nevada (SCN) in June 2025, which is expected to provide access to 3,000+ monthly sleep patients. Vivos Therapeutics, Inc. (VVOS) is focusing on provider-based alliances and acquisitions to capture both diagnostic and treatment revenue directly from these medical practices.

General and specialty dentists (legacy VIP model)

This segment represents the company's historical distribution channel, the Vivos Integrated Provider (VIP) model, which Vivos Therapeutics, Inc. (VVOS) is actively transitioning away from. Following FDA clearance in late 2023, new dentist inquiries increased by 600% over the previous month, and signed dentist enrollment contracts were up 38% sequentially in Q4 2023. However, the Q1 2025 results reflect a planned decline in this legacy revenue stream, with service revenue dropping by $700 thousand year-over-year due to restructuring away from VIP enrollment fees.

Patients seeking alternatives to CPAP therapy

This segment is motivated by the desire for a potentially lasting, non-lifetime intervention, a key differentiator from Continuous Positive Airway Pressure (CPAP) therapy. Vivos Therapeutics, Inc. (VVOS) promotes its C.A.R.E. method as a non-surgical, non-invasive, non-pharmaceutical option for potentially lasting rehabilitation, contrasting with CPAP which requires nightly intervention. The company's product sales volume reflects this demand; in Q1 2025, Vivos Therapeutics, Inc. (VVOS) sold 3,736 oral appliance arches, an 87% increase year-over-year, generating approximately $1.8 million in product revenue.

Here's the quick math on the shift in customer engagement and resulting product volume:

Metric	Q1 2024 Value	Q1 2025 Value	Change
Oral Appliance Arches Shipped	1,996 units	3,736 units	+87%
Product Revenue	$1.7 million	$1.8 million	+8%
Total Revenue	$3.4 million	$3.0 million	-11.8%
Gross Margin	57%	50%	-7 points

What this estimate hides is that the increase in unit volume in Q1 2025 was partly due to higher sales of lower revenue-generating Guide products, which impacts the gross margin percentage. Finance: draft 13-week cash view by Friday.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Vivos Therapeutics, Inc. (VVOS) business as of late 2025, post-acquisition of The Sleep Center of Nevada (SCN). The cost structure is heavily influenced by the operational scaling required to support the new service-based model.

The company's overhead is significant as it integrates and expands its clinical footprint. For the third quarter ended September 30, 2025, General and Administrative (G&A) expenses were reported at $7.884 million (or $7,884,000 in thousands). This figure reflects the increased headcount and associated costs from the SCN acquisition, contributing to the overall operating expenses of $8.7 million for the quarter.

Costs directly tied to service and product delivery are also substantial. The Cost of Sales for oral appliances and sleep center operations, which includes appliance/pediatric/lifeline fees, SCN operations, and treatment center support costs, totaled approximately $2.846 million for Q3 2025. This represented an 87 percent increase year-over-year for the quarter.

Key cost drivers within the operating expenses include personnel investments:

• Personnel costs for Sleep Optimization (SO) teams and clinical staff are rising to meet patient demand.
• For the nine months ended September 30, 2025, G&A included approximately $1.1 million associated with salaries and wages for additional personnel.
• Management is working to ramp up SO teams, which have an expected 30 to 60-day initial ramp time to become fully functional.

Financing costs are also a component of the cost structure, stemming from the debt taken on to support the strategic pivot. The Interest expense on acquisition-related debt for Q3 2025 is a noted cost, reported at $0.7 million.

The company continues to invest in its core offering, which drives future value but adds to current period costs. This includes Research and development (R&D) for device and protocol improvements, which is an ongoing investment area supporting the proprietary Vivos Method.

Here's a quick look at the key cost components for the three months ended September 30, 2025, compared to the prior year period:

Cost Category	Q3 2025 Amount (in thousands)	Q3 2024 Amount (in thousands)
General and Administrative	7,884	4,487
Cost of Sales	2,846	1,526
Depreciation and Amortization	384	146
Total Operating Expenses	8,711 (Calculated: 7,884 + 403 + 384)	5,000 (Given in context)

Note that Total Operating Expenses in the search result for Q3 2025 is stated as $8.7 million, which is slightly different from the sum of the line items provided in the table ($7,884k + $403k + $384k = $8,671k or $8.671 million). The search result for the nine-month period shows G&A of $19.181 million for Q3 2025.

Vivos Therapeutics, Inc. (VVOS) - Canvas Business Model: Revenue Streams

You're looking at Vivos Therapeutics, Inc.'s (VVOS) revenue streams as of late 2025, which clearly show the company's strategic pivot away from its legacy model. The numbers reflect the first full quarter impact of the June 10, 2025, acquisition of The Sleep Center of Nevada (SCN).

The revenue composition is shifting heavily toward direct medical service delivery. Here's the quick math on the new core revenue drivers for the third quarter of 2025:

Revenue Stream Component	Q3 2025 Amount
Diagnostic Sleep Testing Services Revenue (from SCN)	$2.2 million
Treatment Center Revenue (from SCN operations)	$1.3 million
Total Confirmed SCN Service Revenue	$3.5 million

The overall revenue picture for the quarter is built from these new streams, plus product sales, while the old model fades. Total Q3 2025 revenue was reported at $6.8 million, up 78% sequentially over Q2 2025.

The key revenue streams you need to track are:

• Service revenue from sleep testing and treatment centers of $4.6 million in Q3 2025.
• Product revenue from sales of oral appliance arches of $2.2 million in Q3 2025.
• Treatment center revenue from SCN operations of $1.3 million in Q3 2025.
• Diagnostic sleep testing services revenue from SCN of $2.2 million in Q3 2025.

The legacy stream is definitely shrinking, which is by design. Vivos Therapeutics is actively weaning itself off the old way of doing business. The legacy Vivos Integrated Provider (VIP) enrollment fees are decreasing, and management has stated they expect to be finished recognizing any such legacy revenue by the end of 2026. For the nine months ended September 30, 2025, this legacy revenue saw a decrease of approximately $2.6 million compared to the prior year period, showing how quickly the transition is taking hold. Honestly, if onboarding takes longer than expected, churn risk rises, but the stated goal is clear.

Here are the other key financial data points related to revenue for the nine months ended September 30, 2025:

• Nine-month total revenue reached $13.6 million.
• Nine-month revenue represented a 20% increase compared to the same period in 2024.
• Gross margin for Q3 2025 was 58%, down from 60% in Q3 2024.

Finance: draft 13-week cash view by Friday.